知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.021 seconds)

    METHOD FOR PRODUCING PEPTIDE COMPOUND
    2.
    发明申请
    METHOD FOR PRODUCING PEPTIDE COMPOUND 有权

    公开(公告)号：US20220372069A1

    公开(公告)日：2022-11-24

    申请号：US17763185

    申请日：2020-09-14

    Applicant: NISSAN CHEMICAL CORPORATION ,  PEPTIDREAM INC.

    Inventor： Keisuke MORODOME ,  Michiharu HANDA

    IPC: C07K1/10

    Abstract: An object of the present invention is to provide a method for producing a peptide with high efficiency, and a method for producing a peptide which comprises the following steps (1) and (2): (1) a step of mixing an N-protected amino acid or an N-protected peptide with a carboxylic acid halide represented by the formula (I) (wherein X represents a halogen atom, R1, R2 and R3 each independently represent an aliphatic hydrocarbon group which may have a substituent, and a total number of the carbon atoms in R1, R2 and R3 is 3 to 40); and (2) a step of mixing the product obtained in the step (1) and a C-protected amino acid or a C-protected peptide is provided.

    Thrombospondin 1-binding peptide
    3.
    发明授权
    Thrombospondin 1-binding peptide 有权

    公开(公告)号：US11149066B2

    公开(公告)日：2021-10-19

    申请号：US16332746

    申请日：2017-09-13

    Applicant: DAIICHI SANKYO COMPANY, LIMITED ,  PeptiDream Inc.

    Inventor： Takahiro Yamaguchi ,  Yutaka Mori ,  Hironao Saito ,  Hideki Kubota ,  Akihiro Furukawa ,  Eri Otsuka ,  Yutaka Ishigai ,  Hiroshi Ijiri ,  Patrick Reid

    IPC: C07K7/64 ,  A61K38/00

    Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.
    Specifically provided is a macrocyclic polypeptide represented by formula (I) [wherein A is selected from the linking groups A1 to A6; Xaa1 is a residue of an aliphatic amino acid, an aromatic amino acid, a basic amino acid, a neutral amino acid, or an acidic amino acid, or is absent; Xaa2 is a residue of an aromatic amino acid or a neutral amino acid; Xaa3 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid; Xaa4 is Ser, Thr, Ala, or mS; Xaa5 is Gly or Ser; Xaa6 is a residue of a basic amino acid or a neutral amino acid; Xaa7 is a residue of a neutral amino acid or an acidic amino acid; Xaa8 is a residue of an aromatic amino acid; Xaa9 is a residue of an aliphatic amino acid, a neutral amino acid, or an aromatic amino acid; Xaa10 is a residue of a basic amino acid, an aliphatic amino acid, an aromatic amino acid, or a neutral amino acid; Xaa11 is a residue of an aromatic amino acid; and Xaa12 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid], or a pharmacologically acceptable salt thereof.

    HEMAGGLUTININ-BINDING PEPTIDE
    5.
    发明公开
    HEMAGGLUTININ-BINDING PEPTIDE 审中-公开

    公开(公告)号：US20240228544A1

    公开(公告)日：2024-07-11

    申请号：US17432072

    申请日：2020-02-17

    Applicant: PeptiDream Inc.

    Inventor： Keiichi MASUYA ,  Masaki OHUCHI

    IPC: C07K7/64 ,  A61K38/00 ,  A61P31/16 ,  G01N33/569

    CPC classification number: C07K7/64 ,  A61P31/16 ,  G01N33/56983 ,  A61K38/00 ,  G01N2333/11 ,  G01N2469/10

    Abstract: [Problem to be solved] To provide a compound having markedly higher antiviral activity than iHA 100, an intermediate for producing the compound, and a medical drug, or the like, containing the high-activity compound above. [Solution] The invention relates to a hemagglutinin-binding peptide, a pharmaceutically acceptable salts, or a solvate thereof, the hemagglutinin-binding peptide being: (1) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2: Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys (SEQ ID NO: 1), Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys-Lys (SEQ ID NO: 2), or the like.

    METHOD FOR PRODUCING PEPTIDE COMPOUND
    9.
    发明申请
    METHOD FOR PRODUCING PEPTIDE COMPOUND 审中-公开

    公开(公告)号：US20200291061A1

    公开(公告)日：2020-09-17

    申请号：US16753001

    申请日：2018-10-03

    Applicant: NISSAN CHEMICAL CORPORATION ,  PeptiDream Inc.

    Inventor： Akihiro NAGAYA ,  Michiharu HANDA ,  Naohiko YASUDA ,  Madoka YOSHINO ,  Yutaka KOBAYASHI ,  Keiichi MASUYA

    IPC: C07K1/06 ,  C07K7/06 ,  C07K5/087 ,  C07F7/18 ,  C07K5/107

    Abstract: A method for producing a peptide by conducting steps (1) condensing an N-protected amino acid or an N-protected peptide to an N-terminus of a C-protected amino acid or a C-protected peptide represented by formula (II): wherein Y represents an amino acid or a peptide with an unprotected N-terminus; R1, R2 and R3 each independently represent an optionally substituted aliphatic hydrocarbon group, an optionally substituted aromatic hydrocarbon group, or —OR4 (wherein R4 represents an optionally substituted aliphatic or aromatic hydrocarbon group; two of R1, R2 and R3 may form a 5- to 7-membered ring together with the Si atom to which they are bonded; and the R1R2R3Si group has 8 or more carbon atoms and is bonded to a C-terminus of an amino acid or a peptide in Y, and (2) removing the protective group at the N-terminus of the peptide obtained in step (1).

    Method for producing peptide library, peptide library, and screening method
    10.
    发明授权
    Method for producing peptide library, peptide library, and screening method 有权

    公开(公告)号：US10711268B2

    公开(公告)日：2020-07-14

    申请号：US14889868

    申请日：2014-05-12

    Applicant: The University of Tokyo ,  PeptiDream Inc.

    Inventor： Hiroshi Murakami ,  Takashi Kawakami ,  Patrick Reid ,  Toru Sasaki

    IPC: C12N15/10 ,  C12N15/67

    Abstract: An object of the present invention is to provide a method for producing a peptide library capable of incorporating an arbitrary number of arbitrary proteinogenic and/or non-proteinogenic amino acids in an arbitrary site. The invention provides a method for producing a peptide library including 1×106 or more kinds of peptides containing amino acids encoded by N1N2N3, including a step of preparing an mRNA library including mRNAs which encode peptides of the peptide library and each contain at least one N1N2N3; and a step of translating each mRNA of the mRNA library in a cell-free translation system added with tRNA containing an anticodon to any one of N1N2N3 codons and charged with an amino acid corresponding to the codon (wherein, N1, N2, and N3 are each independently selected from adenine (A), guanine (G), cytosine (C), and uracil (U) and an arbitrary amino acid is reassigned to each N1N2N3).

Patent Agency Ranking